跳至主要内容
临床试验/NCT02110108
NCT02110108已完成不适用

Study for the RevLite Laser System for Facial Solar Lentigines

Cynosure, Inc.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2014年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale

研究概览

简要总结

The purpose of this study is to evaluate the effects of the Revlite Laser System for treatment of facial solar lentigines

详细描述

Prospective facial study using the revlite laser to treat pigmentation caused by sun damage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Is a healthy male or female between 18 and 60 years old.
  • Is Fitzpatrick Skin types I-III
  • Is willing to consent to participate in the study.
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.
  • Has clinically determined mild to severe facial mottled pigmentation (solar lentigines) on the face.

排除标准

  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  • Is hypersensitive to light exposure OR takes photo sensitized medication.
  • Has active or localized systemic infections.
  • Has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin {greater than 81 mg per day}).
  • Has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  • Is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study.
  • Has used Accutane within 6 months prior to enrollment.
  • Has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
  • Has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
  • Has a history of keloids.
  • Has evidence of compromised wound healing.
  • Has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.
  • Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.

结局指标

主要结局

Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale

时间窗: 1 month post last treatment

Photos taken at baseline will be compared to photos taken 1 month post last treatment to assess the level of improvement using the Global Aesthetic Improvement Scale. This evaluation is blinded. This scale ranges from -1 to 3, where -1 is worsened, 0 is no change, 1 is improved, 2 is much improved, and 3 is very much improved.

次要结局

  • Physician Satisfaction Questionnaire(1 month post last treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验